A Study Of PF-06263507 In Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Checked against the public recordLast updated Jan 9, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Pfizer
- Interventions being studied
- Drug: PF-06263507; Drug: PF-06263507
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for which no standard therapy is available. * Performance Status of 0 or 1. * Adequate bone marrow, kidney, liver, and heart function. Exclusion Criteria: * Brain metastases requiring steroids. * Major surgery or anti-cancer therapy within 4 weeks of study treatment start. * Active bacterial, fungal or viral infection.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Brigham and Women's HospitalBoston, Massachusetts
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Karmanos Cancer InstituteDetroit, Michigan
- Fox Chase Cancer CenterPhiladelphia, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 9, 2019. Always confirm current availability with the study team.